SGLT2 inhibitors are drugs originally developed to lower blood sugar, but have shown significant protective effects on the kidneys[1][2]. A bibliometric analysis of 1,561 publications from 2009 to 2025 showed a constant increase in the number of studies devoted to this topic[1]. The United States is the leading country in this research, with universities such as the University of Toronto and the University of Groningen[1] making significant contributions. Research has gradually moved from investigating effects on blood sugar control to studying the protection of multiple organs, including the kidney, expanding to include non-diabetic patients with chronic kidney disease[1]. New mechanistic research is focused on understanding the effects of SGLT2 inhibitors on inflammation, oxidative stress and cell death[1]. SGLT2 inhibitors represent a promising approach in the treatment of kidney diseases, while future research should focus on elucidating their underlying mechanisms, long-term safety, and developing individualized treatment strategies[1].